TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States.
Dr Forte’s presentation will be on critical success factors for a successful transition of cell therapy candidates to the clinic. The presentation is scheduled for Monday, January 26, 2015 at 14.30 p.m. EST. A roundtable debate discussing the most important topics raised will follow the presentation.
Dr. Forte will use as examples TxCell’s lead product candidate, Ovasave(R) and second product candidate, Col-Treg from TxCell’s innovative proprietary ASTrIA technological platform. Ovasave is targeted at refractory Crohn’s disease and is currently evaluated in a placebo-controlled phase IIb study. Col-Treg is in development for the rare eye disease autoimmune uveitis. Col-Treg is planned to move into a first clinical study in the first half of 2015.
The key elements in the presentation include gathering strong pre-clinical and preliminary clinical data. Dr. Forte will also cover key process development activities necessary to provide the most robust and transferable manufacturing process and business model establishment and the development of a clear regulatory strategy. Dr. Forte will also present a roundup, from his perspective, on market access including economic viability and therapeutic adoption.
“Patients with chronic inflammatory and autoimmune diseases that have no current therapeutic options continue to present significant unmet medical needs. As TxCell is one of the most advanced companies in the field of T-cell immunotherapy, we share our experiences regarding the development of innovative therapeutic approaches. This will benefit of the entire scientific community,” said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell. “The Cell & Gene Therapy Forum 2015 is an ideal event to position biotechnology companies developing new value-adding treatments and strategies, like TxCell’s personalized antigen specific Treg cell-based therapies.”
The Cell & Gene Therapy Forum is a meeting designed to help advance regulatory, manufacturing, research and commercial strategies and drive cell and gene therapy products forward. The Forum enables to gather executives from biotechnology companies, representatives of big pharma and big biotech, regulators, and public and private investors.